UPDATE: Cantor Fitzgerald Initiates Buy, $17 PT on Fluidigm Corporation on Portfolio Differentiation

Cantor Fitzgerald initiates its coverage on Fluidigm Corporation

with a Buy rating and a price target of $17 a share. Cantor Fitzgerald says, "Despite its size (~$43mm in 2011 revenues), we think FLDM has built a highly differentiated product portfolio for the emerging (and potentially significant) market opportunity in single cell genomics. Although the uncertain academic funding environment and increasing competition in the next generation sequencing (NGS) sample prep business could be near-term headwinds, we think FLDM is one of the few companies in the life science tools sector with the potential to deliver 20+% top line growth over the next several years." FLDM closed at $14.72 on Tuesday.